GLP-1 cost in 2026: insurance, cash price, and every path to coverage

$1,349 a month. That is the number most people see first.

Wegovy's list price sits at roughly $1,349 per month in the United States. Zepbound lists at about $1,059. And Foundayo, the oral GLP-1 that Lilly launched in April 2026, starts at $149. Those are the sticker prices. Almost nobody pays them.

The real cost depends on which of about six different payment lanes you end up in — commercial insurance with a prior authorization, Medicare Part D after July 1, a manufacturer savings card, LillyDirect cash pay, a GoodRx coupon, or an HSA/FSA draw with a letter of medical necessity. Each one has its own paperwork, its own timeline, and its own version of the word "covered."

This is the part that makes people give up before they fill the first prescription. The drug works. The access system around it is a maze. Here is how each lane works right now, what it costs, and what to do when the first answer is no.

What every GLP-1 costs in May 2026 (list price vs. real price)

List price is the number on the pharmacy shelf before insurance, coupons, or manufacturer programs touch it. Think of it like a hotel rack rate — almost nobody pays it, but it sets the ceiling.

Ozempic deserves a note here. It is FDA-approved for type 2 diabetes, not obesity. Prescribers sometimes write it off-label for weight loss, but insurance companies routinely deny coverage for that use. If weight management is the goal, Wegovy is the on-label semaglutide option — same molecule, higher dose, different indication.

Commercial insurance: the PA dance

Most employer-sponsored and ACA marketplace plans will cover at least one GLP-1 for obesity, but almost none of them make it easy. The standard sequence goes like this:

1. Your doctor writes a prescription.
2. The pharmacy runs it through your plan's PBM (pharmacy benefit manager — usually CVS Caremark, Express Scripts, or OptumRx).
3. The PBM flags it as tier 4 or tier 5 specialty and requires a prior authorization.
4. Your doctor's office submits the PA, including diagnosis codes, BMI documentation, and often proof of prior treatment failure (you tried diet, exercise, maybe metformin first).
5. The PBM approves or denies. If denied, you appeal.

That whole process can take 5 to 21 business days. Some plans run it faster. Some drag it past a month.

The formulary status is the first thing to check. Call the number on the back of your insurance card and ask: "Is Wegovy on formulary? What tier? Does it require a PA?" Write down the answers — including the name of the person you spoke with and the reference number. You will need those later if anything gets denied.

If your plan covers Mounjaro for type 2 diabetes but not Zepbound for obesity, and you happen to have both conditions, your doctor may be able to prescribe Mounjaro instead. Same molecule. Different label. Sometimes a faster approval path.

When the PA gets denied — the appeal playbook

A denial is not the end. It is the beginning of a second, more specific conversation.

The most common denial reasons for GLP-1 prior authorizations:

• "Not medically necessary." The PBM wants more documentation. Your doctor needs to submit chart notes showing BMI over 30 (or 27 with comorbidities), plus evidence that behavioral interventions alone were insufficient.
• "Step therapy required." The PBM wants you to try a cheaper drug first — often metformin, phentermine, or generic liraglutide (Saxenda's generic). Your doctor documents the prior failure.
• "Not on formulary." The plan covers a different GLP-1 than the one prescribed. Ask which one is preferred and whether your doctor can switch.
• "Quantity limit exceeded." Usually a dosing issue during titration. Fixable with a dosing-exception request.

The appeal itself is a letter — from your doctor, on your doctor's letterhead, addressed to the PBM's medical director. It should include:

• Your diagnosis (obesity with ICD-10 code E66.01, or relevant comorbidity codes)
• Your BMI history over the past 12 months
• A list of treatments you have already tried and why they were insufficient
• Clinical rationale for the specific drug requested (peer-reviewed study citations help — STEP 1 for Wegovy, SURMOUNT-1 for Zepbound)
• Your doctor's direct contact for peer-to-peer review

Most PBMs allow a peer-to-peer call where your prescribing doctor speaks directly with the PBM's reviewing physician. That call resolves more denials than the paper appeal alone. Ask your doctor's office if they do peer-to-peer reviews — not all offices will, but the ones that do have a notably higher overturn rate.

Medicare Part D: July 1, 2026 changes everything

For 67 million Medicare beneficiaries, July 1, 2026 is circled on the calendar. That is when Medicare Part D begins covering GLP-1 medications for obesity under the expanded benefit approved in late 2025.

Here is what that means in practice:

Before July 2026, Medicare Part D explicitly excluded anti-obesity medications. The only workaround was Wegovy's 2024 cardiovascular risk-reduction indication (the SELECT trial), which let some Medicare patients get it covered under the heart-disease label rather than the obesity label. That loophole required a documented history of cardiovascular disease and was not available to most beneficiaries who wanted the drug for weight management.

After July 1, the obesity indication itself becomes a covered reason. That removes the need for the CV workaround.

One thing to plan for: pharmacies and PBMs will be flooded with new Part D GLP-1 prescriptions in July. If you are a Medicare patient planning to start, ask your doctor to submit the PA in mid-June so the approval is in place before the coverage window opens. That is worth mentioning at your next appointment.

Medicaid: 50 states, 50 different answers

Medicaid coverage for GLP-1 obesity medications varies by state, and "varies" is an understatement. Some states cover Wegovy with a PA. Some exclude all anti-obesity drugs from the formulary. Some cover tirzepatide for type 2 diabetes but not for obesity.

There is no single lookup tool that gives you a reliable state-by-state answer in real time. The closest thing is calling your state's Medicaid pharmacy helpline directly. If you are on a Medicaid managed-care plan (most states contract with companies like Centene, Molina, or UnitedHealthcare Community Plan), call the managed-care plan — not the state — because the plan's formulary may differ from the state's fee-for-service list.

Medicaid expansion states generally have broader formularies, but that is a trend, not a guarantee. Worth checking even if you have been told no before — formularies update quarterly.

Manufacturer savings: NovoCare, LillyDirect, and the Hims deal

The two GLP-1 manufacturers run their own savings programs, and each one works differently.

NovoCare (Novo Nordisk — Wegovy, Ozempic)

• Savings card for commercially insured patients: up to $500 off per month.
• Does not apply to Medicare, Medicaid, or other government insurance.
• You activate it through novocare.com or by calling 1-888-809-3942.
• The savings card brings some commercially insured copays to $0–$25 per fill.

LillyDirect (Eli Lilly — Zepbound, Mounjaro, Foundayo)

• Cash-pay program: $549–$599/month for Zepbound and Mounjaro, shipped directly.
• No insurance required. No PA. No formulary fight.
• Foundayo at $149/month through LillyDirect.
• Lilly also runs a savings card for commercially insured patients.

Hims × Novo Nordisk deal (March 2026)

• Branded semaglutide through Hims at $39 for the first month.
• Subsequent months at negotiated pricing through the Hims platform.
• This is a telehealth-first model — you get a prescription through a Hims clinician.
• Only for patients who meet the clinical criteria.

The Hims deal is new enough that long-term pricing details past the first month are still settling. If you are considering it, ask specifically about month 2 and month 3 pricing before committing — the $39 first-month number is the attention-getter, but the sustained cost is what matters.

HSA, FSA, and the letter of medical necessity

GLP-1 medications are generally eligible expenses under Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA), but most account administrators require a Letter of Medical Necessity (LMN) from your doctor.

The LMN is short — usually one page. It should state:

• Your diagnosis (obesity or a weight-related comorbidity)
• The prescribed medication and why it is medically necessary
• That the treatment is not cosmetic

Some HSA/FSA administrators auto-approve GLP-1 claims with an LMN on file. Others require you to pay out of pocket and submit for reimbursement. Ask your administrator which process they use before your first fill.

One angle people overlook: if your commercial insurance denies the PA and you end up paying cash (via LillyDirect or GoodRx), you can still run that expense through your HSA or FSA with the LMN. The insurance denial does not disqualify the HSA/FSA eligibility. The letter from your doctor is what matters.

A PA denial plus an HSA with a Letter of Medical Necessity can actually be a faster path than waiting 3 weeks for the PBM to approve. You pay cash, get reimbursed from your own pre-tax account, and start the medication this week instead of next month.

GoodRx and cash-pay discounts

For patients paying entirely out of pocket — no insurance, no manufacturer program — GoodRx and similar discount-card services can reduce the pharmacy price, though the savings on brand-name GLP-1s are modest compared to what they save on generic drugs.

Where GoodRx helps most in the GLP-1 space:

• Generic liraglutide (Saxenda's generic, available since 2024): cash price drops meaningfully with a discount card. Often $150–$250/month.
• Ozempic and Wegovy: discounts exist but the final price still lands in the $800–$1,100 range. Not cheap. But better than $1,349.
• Zepbound and Mounjaro: GoodRx discounts are minimal when LillyDirect already offers $549–$599 cash.

GoodRx is not insurance. The pharmacy applies the discount card at the counter, and the price varies by pharmacy — Costco, Walmart, and independent pharmacies sometimes beat chain pharmacies by $50–$100 on the same drug.

Compounded GLP-1s: the shrinking option

Through most of 2024 and 2025, compounded semaglutide and tirzepatide were the cheapest path to a GLP-1 — sometimes $200–$400 per month from 503A or 503B compounding pharmacies. That path is narrowing fast.

The FDA warned 30 telehealth companies in March 2026 about misleading marketing of compounded GLP-1 products. The enforcement grace period that allowed mass compounding during the GLP-1 shortage is expiring as branded supply stabilizes. By May 2026, patients on compounded GLP-1s are in an increasingly uncertain position.

This does not mean every compounded product disappears overnight. Patient-specific compounding from licensed 503A pharmacies — where a doctor writes a prescription for one patient and a pharmacist fills it — is still legal. What is getting shut down is the mass-production telehealth subscription model that treated compounding as a loophole for cheaper branded drugs.

If you are currently on a compounded GLP-1, the practical question is whether your source will still be operating in three months. Worth reading the full breakdown on what comes after the crackdown.

Foundayo at $149: does it change the math?

Foundayo (orforglipron) landed in April 2026 at $149 per month — roughly 89% cheaper than Wegovy's list price and 86% cheaper than Zepbound's. It is an oral tablet, once daily, no fasting requirement.

That $149 price point is intentional. Lilly priced Foundayo to undercut not just the branded injectable competition but also the compounded GLP-1 market. At $149 with no injection, no cold-chain shipping, and no dose-mixing math, Foundayo removes most of the friction points that pushed patients toward compounding in the first place.

The ATTAIN trials showed roughly 8–10% body weight reduction at the highest oral dose over 72 weeks. That is less than Wegovy's 15.2% (STEP 1) or Zepbound's 22.5% (SURMOUNT-1) at top injectable doses. But for patients who were paying $300–$400 for a compounded injectable, $149 for a branded FDA-approved oral pill is a different value proposition.

The cost conversation around Foundayo is less about insurance and more about whether the lower price point makes insurance irrelevant for some patients. If your copay with insurance would be $50, sure, use insurance. But if your PA is stuck in a 3-week queue and you could start today for $149 at LillyDirect — some patients are choosing the cash route.

What to check before filling the first prescription

Before you leave the pharmacy counter (or click "confirm" on a mail-order site), verify these five things:

1. What is your actual out-of-pocket cost for this fill? Not the estimated cost. The real number after insurance adjudication. Ask the pharmacist to run it through before you commit.

2. Is a manufacturer savings card applied? If you have commercial insurance and you are filling Wegovy, the NovoCare card should be stacked on top of your insurance. If it is not applied, you could be overpaying by hundreds.

3. What dose are you filling? GLP-1s titrate up over weeks. The first fill should be the starting dose (Wegovy 0.25 mg, Zepbound 2.5 mg, Foundayo at the labeled starting dose). If the pharmacy is filling a maintenance dose on day one, something is wrong.

4. Does your plan use a specialty pharmacy? Many PBMs route GLP-1 prescriptions to their own mail-order specialty pharmacy (CVS Specialty, Accredo, BriovaRx). Your local CVS or Walgreens may not be able to fill it. Ask your plan before the doctor sends the script.

5. What is the refill timeline? Most GLP-1s are a 28-day supply. Some plans allow a 90-day mail-order fill at a lower per-unit cost. Ask about both options.

The global picture — costs outside the U.S.

GLP-1 pricing looks different in every country, and not always in the direction you would expect.

The pattern: most countries cover GLP-1s for type 2 diabetes through their national systems. Coverage for obesity as a standalone indication is rare outside the U.S. and UK. Patients in Korea, Japan, and most of the EU pay entirely out of pocket for weight-management use.

This matters for U.S. readers too — if you travel, your insurance may not cover fills abroad, and prices at foreign pharmacies can be lower or higher depending on the country. It is not a reliable arbitrage.

Questions to bring to your doctor

The cost conversation and the clinical conversation are the same conversation. Bring these to your next visit:

• "Which GLP-1 is on my plan's formulary, and at what tier?" Your doctor's office can check this with an e-prescribing tool, but having the answer yourself gives you leverage.
• "If the PA gets denied, will your office handle the appeal and the peer-to-peer call?" Not every practice does. Knowing upfront saves you weeks of frustration.
• "Should I start with Foundayo at $149 cash while we wait for the PA on Wegovy or Zepbound?" This is a legitimate clinical question — not all patients are good candidates for oral GLP-1s, but some are, and the cost difference during the PA wait is real.
• "Can I use my HSA/FSA, and will you write the LMN?" One appointment, one letter, ongoing savings.
• "What is the titration schedule, and how many fills will I need before reaching the maintenance dose?" This affects total cost over the first 4–5 months. Wegovy titrates over 16–20 weeks before reaching the 2.4 mg maintenance dose. Budget accordingly.

If you are a Medicare patient and your appointment is in May or June, ask whether your doctor can submit the PA before July 1 so coverage is in place the day the benefit opens.

The realistic picture

GLP-1 access in 2026 is better than it was in 2024. Medicare coverage opening in July is the single biggest expansion of access since these drugs launched. Foundayo at $149 undercuts the compounded market on price while offering an FDA-approved product. Manufacturer programs from Novo Nordisk and Lilly continue to reduce copays for commercially insured patients.

But "better" is not "solved." A PA denial still takes weeks to appeal. Medicaid coverage remains a patchwork. Patients without insurance and without eligibility for manufacturer programs face real four-figure monthly costs on the injectables.

The patients who navigate this most successfully tend to do three things: they check their formulary status before the prescription is written, they ask their doctor to handle the PA aggressively (including peer-to-peer calls), and they stack every available discount — insurance plus savings card plus HSA/FSA.

Worth noting: GLP-1 side effects are real and dose-dependent. The cost question and the tolerability question should be part of the same decision. Paying $1,000 a month for a drug you cannot tolerate past week three is the most expensive outcome. Start at the lowest dose, titrate slowly, and give your body time to adjust before committing to the full monthly expense at maintenance dose.

The cost maze is real. But it has exits. Most patients find one if they are willing to work the system — or have a doctor's office that does it for them.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app